Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 295

1.

Intravenous delivery of targeted liposomes to amyloid-β pathology in APP/PSEN1 transgenic mice.

Tanifum EA, Dasgupta I, Srivastava M, Bhavane RC, Sun L, Berridge J, Pourgarzham H, Kamath R, Espinosa G, Cook SC, Eriksen JL, Annapragada A.

PLoS One. 2012;7(10):e48515. doi: 10.1371/journal.pone.0048515. Epub 2012 Oct 31.

2.

Abeta deposition and related pathology in an APP x PS1 transgenic mouse model of Alzheimer's disease.

Howlett DR, Bowler K, Soden PE, Riddell D, Davis JB, Richardson JC, Burbidge SA, Gonzalez MI, Irving EA, Lawman A, Miglio G, Dawson EL, Howlett ER, Hussain I.

Histol Histopathol. 2008 Jan;23(1):67-76. doi: 10.14670/HH-23.67.

PMID:
17952859
3.

Deposition of mouse amyloid beta in human APP/PS1 double and single AD model transgenic mice.

van Groen T, Kiliaan AJ, Kadish I.

Neurobiol Dis. 2006 Sep;23(3):653-62. Epub 2006 Jul 10.

PMID:
16829076
4.

Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease.

Magga J, Puli L, Pihlaja R, Kanninen K, Neulamaa S, Malm T, Härtig W, Grosche J, Goldsteins G, Tanila H, Koistinaho J, Koistinaho M.

J Neuroinflammation. 2010 Dec 7;7:90. doi: 10.1186/1742-2094-7-90.

5.
6.

Transplanted astrocytes internalize deposited beta-amyloid peptides in a transgenic mouse model of Alzheimer's disease.

Pihlaja R, Koistinaho J, Malm T, Sikkilä H, Vainio S, Koistinaho M.

Glia. 2008 Jan 15;56(2):154-63.

PMID:
18004725
7.

Pharmacokinetics and amyloid plaque targeting ability of a novel peptide-based magnetic resonance contrast agent in wild-type and Alzheimer's disease transgenic mice.

Kandimalla KK, Wengenack TM, Curran GL, Gilles EJ, Poduslo JF.

J Pharmacol Exp Ther. 2007 Aug;322(2):541-9. Epub 2007 May 15.

8.

A transgenic Alzheimer rat with plaques, tau pathology, behavioral impairment, oligomeric aβ, and frank neuronal loss.

Cohen RM, Rezai-Zadeh K, Weitz TM, Rentsendorj A, Gate D, Spivak I, Bholat Y, Vasilevko V, Glabe CG, Breunig JJ, Rakic P, Davtyan H, Agadjanyan MG, Kepe V, Barrio JR, Bannykh S, Szekely CA, Pechnick RN, Town T.

J Neurosci. 2013 Apr 10;33(15):6245-56. doi: 10.1523/JNEUROSCI.3672-12.2013.

9.

The effect of focal brain injury on beta-amyloid plaque deposition, inflammation and synapses in the APP/PS1 mouse model of Alzheimer's disease.

Collins JM, King AE, Woodhouse A, Kirkcaldie MT, Vickers JC.

Exp Neurol. 2015 May;267:219-29. doi: 10.1016/j.expneurol.2015.02.034. Epub 2015 Mar 4.

PMID:
25747037
10.

Human APOE4 increases microglia reactivity at Aβ plaques in a mouse model of Aβ deposition.

Rodriguez GA, Tai LM, LaDu MJ, Rebeck GW.

J Neuroinflammation. 2014 Jun 19;11:111. doi: 10.1186/1742-2094-11-111.

11.

Coenzyme Q10 reduces beta-amyloid plaque in an APP/PS1 transgenic mouse model of Alzheimer's disease.

Yang X, Dai G, Li G, Yang ES.

J Mol Neurosci. 2010 May;41(1):110-3. doi: 10.1007/s12031-009-9297-1. Epub 2009 Oct 16.

PMID:
19834824
12.

High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain.

Güntert A, Döbeli H, Bohrmann B.

Neuroscience. 2006 Dec 1;143(2):461-75. Epub 2006 Sep 27.

PMID:
17008022
13.

Nitration of tyrosine 10 critically enhances amyloid β aggregation and plaque formation.

Kummer MP, Hermes M, Delekarte A, Hammerschmidt T, Kumar S, Terwel D, Walter J, Pape HC, König S, Roeber S, Jessen F, Klockgether T, Korte M, Heneka MT.

Neuron. 2011 Sep 8;71(5):833-44. doi: 10.1016/j.neuron.2011.07.001.

14.

Autophagy enhancer carbamazepine alleviates memory deficits and cerebral amyloid-β pathology in a mouse model of Alzheimer's disease.

Li L, Zhang S, Zhang X, Li T, Tang Y, Liu H, Yang W, Le W.

Curr Alzheimer Res. 2013 May 1;10(4):433-41.

PMID:
23305067
15.

Involvement of receptor tyrosine kinase Tyro3 in amyloidogenic APP processing and β-amyloid deposition in Alzheimer's disease models.

Zheng Y, Wang Q, Xiao B, Lu Q, Wang Y, Wang X.

PLoS One. 2012;7(6):e39035. doi: 10.1371/journal.pone.0039035. Epub 2012 Jun 11.

16.

K114 inhibits A-beta aggregation and inflammation in vitro and in vivo in AD/Tg mice.

Zhang YH, Mann D, Raymick J, Sarkar S, Paule MG, Lahiri DK, Dumas M, Bell-Cohen A, Schmued LC.

Curr Alzheimer Res. 2014 Mar;11(3):299-308.

PMID:
24552157
17.

Cerebral amyloid β(42) deposits and microvascular pathology in ageing baboons.

Ndung'u M, Härtig W, Wegner F, Mwenda JM, Low RW, Akinyemi RO, Kalaria RN.

Neuropathol Appl Neurobiol. 2012 Aug;38(5):487-99. doi: 10.1111/j.1365-2990.2011.01246.x.

PMID:
22126319
18.

Imaging brain amyloid of Alzheimer disease in vivo in transgenic mice with an Abeta peptide radiopharmaceutical.

Lee HJ, Zhang Y, Zhu C, Duff K, Pardridge WM.

J Cereb Blood Flow Metab. 2002 Feb;22(2):223-31.

PMID:
11823720
19.

Huntingtin associated protein 1 regulates trafficking of the amyloid precursor protein and modulates amyloid beta levels in neurons.

Yang GZ, Yang M, Lim Y, Lu JJ, Wang TH, Qi JG, Zhong JH, Zhou XF.

J Neurochem. 2012 Sep;122(5):1010-22. doi: 10.1111/j.1471-4159.2012.07845.x.

Supplemental Content

Support Center